Section 7: Post Congress additions最新文献

{"title":"4CPS-191 Switch to benralizumab for severe eosinophilic asthma","authors":"M. Gutiérrez Lorenzo, L. Rodríguez De Francisco, J. Romero Puerto, P. Ciudad Gutiérrez, P. del Valle Moreno","doi":"10.1136/ejhpharm-2022-eahp.403","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.403","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"78 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128286712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5PSQ-054 Endophthalmitis after intravitreal injection with anti-angiogenic drugs: a rare but serious complication","authors":"C. Aparicio Carreño, A. Gándara Ande, A. Fórneas Sangil, B. Fernández González, A. Ayastuy Ruiz, R. Pampín Sánchez, C. Martínez-Múgica Barbosa, A. Fernández González","doi":"10.1136/ejhpharm-2022-eahp.420","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.420","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128570354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-129 Adjust doses of antibiotics in patients with renal insufficiency","authors":"R. Castillejo, A. Aguado Paredes, A. Martinez Suarez, L. Moñino Domínguez, L. Martín Casado, M. Romero González","doi":"10.1136/ejhpharm-2022-eahp.395","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.395","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"2021 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116497614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-105 Cardiovascular risk factors in patients with HIV infection with antiretroviral treatment","authors":"A. Fernández González, C. Aparicio Carreño, A. Gándara Ande, A. Fórneas Sangil, S. Fuertes Camporro, J. Fra Yáñez","doi":"10.1136/ejhpharm-2022-eahp.393","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.393","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125849891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-152 Characterisation of a compounded voriconazole solution for nebulisation and description of its use in the clinical setting","authors":"M. Larrosa García, S. Terradas Campanario, A. Fernández Polo, C. Cañete Ramírez, A. Pau Parra, L. Doménech Moral, D. Campany Herrero, MR Gomez Domingo, M. G. Gorgas Torner","doi":"10.1136/ejhpharm-2022-eahp.399","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.399","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131536418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-091 Analysis of pharmaceutical interventions related to high-risk-drugs in the emergency department","authors":"L. Rico-Pizarro, L. Moreno-Gutiérrez, C. Puivecino-Moreno, Y. Castellanos-Clemente, Mdm García-Gutiérrez, N. Font-Tarres, M. García-Gil","doi":"10.1136/ejhpharm-2022-eahp.390","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.390","url":null,"abstract":"Background and importance Medication errors are frequent in the emergency department (ED) and the most common drugs involved are high-risk-drugs (HRD), which are drugs that are more likely to cause serious or even fatal harm to patients when used incorrectly. Aim and objectives Describe the evolution of pharmaceutical interventions in the ED related to HRD in two comparable time periods and evaluate the acceptance degree. Material and methods Retrospective observational study. All interventions performed in the ED during the periods between July and December 2019 and 2020 were included. The primary endpoint was the percentage of interventions related to HRD and their acceptance percentage. Secondary endpoints were: percentage of interventions related to HRD according to therapeutic group, 2 their acceptance percentage, and the main reasons for intervention (>15%). Interventions were recorded through the electronic prescription programme and were communicated to the responsible physician. The data were processed using Excel 2013. Results A total of 165/494 (33.4%) and 234/731 (32.0%) HRD interventions were performed in 2019 and 2020, respectively. The acceptance percentages were 108/165 (65.5%) and 173/234 (73.9%). The main HRD therapeutic groups on which we intervened and their acceptance percentage in the periods of 2019 and 2020, respectively, were: heparin and parenteral anticoagulants (23.6% (61.5%) and 20.1% (83.0%)), insulins (12.1% (60.0%) and 15.0% (71.4%)), oral anticoagulants (10.9% (66.7%) and 13.2% (83.9%)), opioids (8.5% (71.4%) and 7.7% (77.8%), antipsychotics (7.9% (69.2%) and 6.8% (68.8%)), diuretics (7.3% (50.0%) and 16.7% (61.5%)), sedatives (6.7% (63.6%) and 4.3% (90.0%)), antibiotics (6.1% (80.0%) and 1.3% (100%)), narrow-margin antiepileptics (4.2% (71.4%) and 5.6% (69.2%)) and other groups (<5%). The main intervention reasons (>15%) on the most prevalent therapeutic groups (>10%) were in the 2019 and 2020 periods, respectively: heparin and parenteral anticoagulants (need for treatment (66.7% and 57.4%)); insulins (need for treatment (60.0% and 41.2%), medication reconciliation (15.0% and 23.5%), inadequate dose (10.0% and 17.6%)); oral anticoagulants (medication reconciliation (55.6% and 41.9%), inadequate dose (11.1% and 19.4%)); diuretics (medication reconciliation (50.0% and 43.6%) and renal insufficiency (16.7% and 12.8%)). Conclusion and relevance The percentage of interventions related to HRD was similar in both periods; however, there was an increase in acceptance degree in the 2020 period. More than a half of HRD interventions were performed on parenteral heparin, insulins, oral anticoagulants, and diuretics. The most prevalent reasons for intervention were the need for additional treatment and medication reconciliation. It seems that the intervention of pharmacists in the ED could improve the safety in the use of HRD.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132534258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3PC-032 Optimising analgosedation in the intensive care unit during the SARS-CoV-2 pandemic","authors":"I. Garcia del Valle, M. Sanmartín Suñer, L. Val Prat, M. Nevot Blanc, P. Marcos Pascua, G. Morla Clavero, M. Garcia Pelaez, G. Baronet Jordana","doi":"10.1136/ejhpharm-2022-eahp.379","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.379","url":null,"abstract":"Background and importanceThe pandemic caused by SARS-CoV-2 evidenced the need for expediting the dispensation and usage process, poorly automated, of narcotic drugs and for optimising the most commonly used perfusions available in the hospital (midazolam, dexmedethomidine, propofol, fentanyl). With this intervention, significant improvements in efficacy and safety were expected, considering the fact that perfusions decrease the risk of infection, medication errors and the workload and exposure of nurses.Aim and objectivesTo elaborate a physicochemical and microbiological stable fentanyl perfusion and to adapt the presentations of drugs (midazolam, dexmedethomidine, propofol, fentanyl) used for analgosedation in COVID-19 patients admitted to the intensive care unit (ICU).Material and methodsA multidisciplinary team formed by intensive care doctors, nurses and clinical pharmacists was created in October 2020 to discuss areas of improvement and effort optimisation.All midazolam and propofol presentations were changed for others of larger volume available on the market. A dexmedethomidine perfusion 2000 mg/250 mL was standardised thanks to previous stability data collected.A new fentanyl perfusion was prepared and validated in sterile conditions after a literature systematic review, microbiological controls in tryptic soy broth (TSB) and thioglycollate broth, and a microbiological risk matrix were done.Fentanyl perfusions were stocked in Pharmacy and individually dispensed according to the infusion speed of each patient. Control numbers were assigned to every preparation to maintain the narcotics’ traceability.ResultsEach perfusion consisted of 1500 μg fentanyl (10 vials 150 μg/3 ml=1 perfusion) diluted in 100 mL sodium chloride 0.9%. The final stability given was 30 days at room temperature (all culture replicates in TSB and thioglycollate broth at days 0, 9 and 30 were negative). The daily number of preparations depended on the epidemiology of the disease. However, a median value of 13 perfusions was dispensed up to a total of 21 ICU beds.Conclusion and relevanceThis model can be extrapolated to other Pharmacy Services as long as volumetric pumps, trained professionals and horizontal laminar flow cabinets are available. The intervention met some of the demands created during the pandemic and helped to slightly attenuate the pressure on healthcare professionals.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"64 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116316130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-070 Study of cardiovascular toxicity associated with ibrutinib treatment","authors":"R. Tamayo Bermejo, JC del Río Valencia, C. Ortega de la Cruz, I. Muñoz Castillo","doi":"10.1136/ejhpharm-2022-eahp.388","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.388","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126114752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"6ER-015 Mutations in the factor VIII gene in our haemophilia A population","authors":"A. Martín López, P. Joy Carmona, CL Díaz Díaz, MÁ Ocaña Gómez, M. Ríos De Paz, M. D. De Dios García, J. Esquivel Negrín, I. González García","doi":"10.1136/ejhpharm-2022-eahp.432","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.432","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"09 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127395411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-253 Differences between pharmaceutical interventions performed on antimicrobials in medical and surgical services","authors":"S. Fernández, S. Ortonobes, N. Soler, M. Florit","doi":"10.1136/ejhpharm-2022-eahp.411","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.411","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127397307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}